Clinical trials: Ovarian Tumor
Cervical, Ovarian
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
Background: Some cancer cells have a large amount of a protein called P-glycoprotein, which can pump certain chemotherapy drugs out of their cells.
- Conditions
- Cervical, Ovarian, Lung, Breast
- Trial name
- NCT00972205
- Testing
- paclitaxel, CBT-1(Registered Trademark), Tc 99m sestamibi
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Urethral Neoplasms, Neoplasms, Urethral
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Background: Gemcitabine and carboplatin are chemotherapy drugs used to treat several types of cancer, including cancer of the pancreas, bladder, ovaries, and lung.
- Conditions
- Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra, Urethral Cancer
- Trial name
- NCT01352962
- Testing
- Gemcitabine, Carboplatin, Lenalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
This study will assess the efficacy and safety of pembrolizumab (MK-3475) monotherapy in female participants with recurrent ovarian cancer (ROC) who have received up to 5 prior lines of treatment including platinum-based…
- Trial name
- NCT02674061
- Testing
- Pembrolizumab
- Volunteers
- 376 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib
This prospective, non-interventional study is designed to evaluate the quality of life of Chinese ovarian cancer patients with long-term niraparib use in a real-world setting.
- Trial name
- NCT06037213
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer
Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer
Preliminary evaluation of the efficacy and safety of paclitaxel for injection (albumin-bound) in combination with carboplatin for first-line chemotherapy of ovarian cancer.
- Trial name
- OC-01 (NCT03818282)
- Testing
- Paclitaxel for injection (albumin-bound)
- Volunteers
- 77 people
- Sponsor
- Huazhong University of Science and Technology
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This phase II trial studies how well first-line treatment of bevacizumab, carboplatin, and paclitaxel work in treating participants with stage III- IV ovarian, primary peritoneal and fallopian tube cancer.
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT01097746
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Mullerian Mixed Tumor of Ovary
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
- Trial name
- NCT02090127
- Testing
- ficlatuzumab
- Where
- United States
- Sponsor
- AVEO Pharmaceuticals, Inc.
Female Reproductive System Neoplasm, Malignant Female Reproductive System Neoplasm
EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery
This trial determines how well eHealth mindful movement and breathing works to improve outcomes in participants undergoing gynecologic surgery.
- Conditions
- Female Reproductive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma
- Trial name
- NCT03379376
- Testing
- Questionnaire Administration, Supportive Care
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Ovarian Cancer
A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable
This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant bevacizumab in participants with initially unresectable, FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer.
- Trial name
- ANTHALYA (NCT01739218)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 15 sites in France
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Polycystic Ovary Syndrome
L-carnitine and COH in PCOS Women Undergoing IVF/ICSI Cycles
The aim of this study was to evaluate the effect of oral L-carnitine supplementation during controlled ovarian stimulation (COS) in patients with polycystic ovary syndrome (PCOS) in a double-blind randomized clinical trial.
- Trial name
- NCT04672720
- Testing
- L-carnitine 1000 Mg
- Where
- Iran
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Royan Institute
Endometrial Cancer, Esophageal Cancer
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
- Trial name
- NCT04044859
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 120 people
- Sponsor
- USWM CT, LLC
Breast Cancer, Colorectal Cancer
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- NCT00709462
- Testing
- CDX1307
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Celldex Therapeutics
Ovarian Neoplasms, Germ Cell Tumors
Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian germ cell tumors (OGCTs) constitute 10% of ovarian tumors in Egypt and mainly affect young females. Teratomas are the most common type.Most of teratomas is benign. However, it is liable for malignant transformation.
- Conditions
- Ovarian Neoplasms, Germ Cell Tumors, Immunohistochemistry
- Trial name
- NCT04283773
- Testing
- p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267), Ki67 antibody (DAKO) for malignant cases only
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Assiut University
Ovulation Disorder, Ovarian Cysts
The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
The purpose of the study is to establish that sustained estrogen levels are the driving force for the LH surge, and are thereby necessary for ovulation to occur.
- Trial name
- NCT01999569
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Colon Cancer
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor.
- Conditions
- Breast Cancer, Colon Cancer, Ovarian Cancer, Endometrium Cancer
- Trial name
- NCT01068483
- Testing
- BKM120
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Complications, Ovarian Cancer
The Impact of the Inflammation Index on Predicting Postoperative Complications in Ovarian Cancer
Advanced-stage ovarian cancer surgery is a procedure that inherently carries a high risk of mortality and morbidity. However, there are some uncertainties regarding whether these complications can be predicted before the…
- Trial name
- NCT06798610
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 228 people
- Sponsor
- Sakarya University
Polycystic Ovary Syndrome
Psychological Traits, Sexuality and Quality of Life in Patients With Polycystic Ovary Syndrome
A prospective assessment of psychological characteristics, quality of life and sexuality in naïve patients.
- Trial name
- NCT03306459
- Testing
- SF-36 (Short Form Health Survey)
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Recurrent Ovarian Carcinoma
Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer
The investigators propose to initiate a study assessing the efficacy and safety of a lower initial dosage of lenvatinib combined with toripalimab in patients suffering from platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT06241105
- Testing
- Lenvatinib+Toripalimab.
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Peking Union Medical College Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.